The company’s Oxymorphone Hydrochloride ER tablets, CII are the generic version of Opana ER.
Opana ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.
Actavis Sales & Marketing vice president Michael Perfetto said Oxymorphone ER tablets offer significant value to customers and patients.
"This launch exemplifies Actavis’ focus, commitment and capability in bringing complex controlled-release products to our customers," Perfetto said.